Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C R Kirman

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Journal of Exposure Science & Environmental Epidemiology|March 11, 2020
Using physiologically-based pharmacokinetic modeling to assess the efficacy of glove materials in reducing internal doses and potential hazards of N-methylpyrrolidone during paint strippingC R Kirman
Regulatory Toxicology and Pharmacology : RTP|November 22, 2011
Quantitative human health risk assessment for 1,3-butadiene based upon ovarian effects in rodentsC R Kirman, R L Grant
Regulatory Toxicology and Pharmacology : RTP|November 8, 2017
Derivation of endogenous equivalent values to support risk assessment and risk management decisions for an endogenous carcinogen: Ethylene oxideC R Kirman, S M Hays
Regulatory Toxicology and Pharmacology : RTP|January 12, 2019
Science peer review for the 21st century: Assessing scientific consensus for decision-making while managing conflict of interests, reviewer and process biasC R Kirman, T W Simon, S M Hays
Regulatory Toxicology and Pharmacology : RTP|February 7, 2016
Derivation of a No-significant-risk-level (NSRL) for dermal exposures to diethanolamineC R Kirman, B Hughes, R A Becker, et al.
Risk Analysis : an Official Publication of the Society for Risk Analysis|May 7, 2005
Using physiologically-based pharmacokinetic modeling to address nonlinear kinetics and changes in rodent physiology and metabolism due to aging and adaptation in deriving reference values for propylene glycol methyl ether and propylene glycol methyl ether acetateC R Kirman, L M Sweeney, R Corley, et al.
Toxicology and Applied Pharmacology|April 9, 2017
Improved physiologically based pharmacokinetic model for oral exposures to chromium in mice, rats, and humans to address temporal variation and sensitive populationsC R Kirman, M Suh, D M Proctor, et al.
Regulatory Toxicology and Pharmacology : RTP|November 19, 2003
Assessing the dose-dependency of allometric scaling performance using physiologically based pharmacokinetic modelingC R Kirman, L M Sweeney, M E Meek, et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|January 27, 2009
Acrylamide: Consideration of species differences and nonlinear processes in estimating risk and safety for human ingestionM L Gargas, C R Kirman, L M Sweeney, et al.
Chemico-Biological Interactions|October 7, 2023
Corrigendum to "An updated lymphohematopoietic and bladder cancers risk evaluation for occupational and environmental exposures to 1,3-butadiene" [Chem. Biol. Interact. 366 (2022) 1-10]C Valdez-Flores, N Erraguntla, R Budinsky, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Journal of Exposure Science & Environmental Epidemiology|March 11, 2020
Using physiologically-based pharmacokinetic modeling to assess the efficacy of glove materials in reducing internal doses and potential hazards of N-methylpyrrolidone during paint strippingC R Kirman
Regulatory Toxicology and Pharmacology : RTP|November 22, 2011
Quantitative human health risk assessment for 1,3-butadiene based upon ovarian effects in rodentsC R Kirman, R L Grant
Regulatory Toxicology and Pharmacology : RTP|November 8, 2017
Derivation of endogenous equivalent values to support risk assessment and risk management decisions for an endogenous carcinogen: Ethylene oxideC R Kirman, S M Hays
Regulatory Toxicology and Pharmacology : RTP|January 12, 2019
Science peer review for the 21st century: Assessing scientific consensus for decision-making while managing conflict of interests, reviewer and process biasC R Kirman, T W Simon, S M Hays
Regulatory Toxicology and Pharmacology : RTP|February 7, 2016
Derivation of a No-significant-risk-level (NSRL) for dermal exposures to diethanolamineC R Kirman, B Hughes, R A Becker, et al.
Risk Analysis : an Official Publication of the Society for Risk Analysis|May 7, 2005
Using physiologically-based pharmacokinetic modeling to address nonlinear kinetics and changes in rodent physiology and metabolism due to aging and adaptation in deriving reference values for propylene glycol methyl ether and propylene glycol methyl ether acetateC R Kirman, L M Sweeney, R Corley, et al.
Toxicology and Applied Pharmacology|April 9, 2017
Improved physiologically based pharmacokinetic model for oral exposures to chromium in mice, rats, and humans to address temporal variation and sensitive populationsC R Kirman, M Suh, D M Proctor, et al.
Regulatory Toxicology and Pharmacology : RTP|November 19, 2003
Assessing the dose-dependency of allometric scaling performance using physiologically based pharmacokinetic modelingC R Kirman, L M Sweeney, M E Meek, et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|January 27, 2009
Acrylamide: Consideration of species differences and nonlinear processes in estimating risk and safety for human ingestionM L Gargas, C R Kirman, L M Sweeney, et al.
Chemico-Biological Interactions|October 7, 2023
Corrigendum to "An updated lymphohematopoietic and bladder cancers risk evaluation for occupational and environmental exposures to 1,3-butadiene" [Chem. Biol. Interact. 366 (2022) 1-10]C Valdez-Flores, N Erraguntla, R Budinsky, et al.
Pageof 4